Phibro Animal Health Corporation (PAHC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Phibro Animal Health Corporation stock (PAHC) is currently trading at $55.48. Phibro Animal Health Corporation PE ratio is 22.46. Phibro Animal Health Corporation PS ratio (Price-to-Sales) is 1.41. Analyst consensus price target for PAHC is $48.50. WallStSmart rates PAHC as Moderate Buy.
- PAHC PE ratio analysis and historical PE chart
- PAHC PS ratio (Price-to-Sales) history and trend
- PAHC intrinsic value — DCF, Graham Number, EPV models
- PAHC stock price prediction 2025 2026 2027 2028 2029 2030
- PAHC fair value vs current price
- PAHC insider transactions and insider buying
- Is PAHC undervalued or overvalued?
- Phibro Animal Health Corporation financial analysis — revenue, earnings, cash flow
- PAHC Piotroski F-Score and Altman Z-Score
- PAHC analyst price target and Smart Rating
Phibro Animal Health Corporation
📊 No data available
Try selecting a different time range
PAHC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Phibro Animal Health Corporation (PAHC)
PAHC trades at a significant discount to its Graham intrinsic value of $105.77, offering a 51% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Phibro Animal Health Corporation (PAHC) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, revenue growth. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Phibro Animal Health Corporation (PAHC) Key Strengths (6)
Every $100 of shareholder equity generates $32 in profit
Earnings per share surging 752.00% year-over-year
96.65% of shares held by major funds and institutions
Paying $1.41 for every $1 of annual revenue
Strong revenue growth at 20.90% annually
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Phibro Animal Health Corporation (PAHC) Areas to Watch (4)
Very expensive at 6.2x book value
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Growth is fairly priced, not cheap, not expensive
Phibro Animal Health Corporation (PAHC) Detailed Analysis Report
Overall Assessment
This company scores 67/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 4.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (1.41) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 31.80%. Growth metrics are encouraging with Revenue Growth at 20.90%, EPS Growth at 752.00%.
The Bear Case
The primary concerns are Price/Book, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (1.66), Price/Book (6.19) suggest expensive pricing. Profitability pressure is visible in Operating Margin at 14.70%, Profit Margin at 6.29%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 31.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 20.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, EPS Growth) and negatives (Price/Book, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PAHC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PAHC's Price-to-Sales ratio of 1.41x trades 107% above its historical average of 0.68x (98th percentile), historically expensive. The current valuation is 7% below its historical high of 1.51x set in Mar 2026, and 539% above its historical low of 0.22x in Nov 2023. Over the past 12 months, the PS ratio has expanded from ~0.4x, reflecting growing market expectations outpacing revenue growth.
Compare PAHC with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Phibro Animal Health Corporation (PAHC) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Phibro Animal Health Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 1.5B with 21% growth year-over-year. Profit margins are thin at 6.3%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 3180.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 8M in free cash flow and 19M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Phibro Animal Health Corporation push profit margins above 15% as the business scales?
Growth sustainability: can Phibro Animal Health Corporation maintain 21%+ revenue growth, or will competition slow it down?
Dividend sustainability with a current yield of 92.0%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 604M is significantly higher than cash (55M). Monitor refinancing risk.
Bottom Line
Phibro Animal Health Corporation offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Phibro Animal Health Corporation(PAHC)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.